Physician profile
Matthew M Mark
NPI 1881782936
$1,604.91
in general payments reported to CMS, 2019-2025
21 companies · $88.23 in 2025
The $88.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $168 · 2021: $220 · 2022: $448 · 2023: $275 · 2024: $174 · 2025: $88.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.91 | 2021-2025 | |
| Pfizer INC. | $244.79 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $149.61 | 2020-2023 | Breztri, Airsupra |
| Novo Nordisk INC | $122.32 | 2019-2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $121.91 | 2021-2023 | |
| Glaxosmithkline, LLC. | $121.46 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $70.72 | 2019-2022 | |
| Allergan, INC. | $60.98 | 2019-2020 | |
| Exact Sciences Corporation | $53.04 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $49.94 | 2023-2024 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.57 | 2022-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $47.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.32 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $39.10 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.84 | 2022-2024 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.07 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $21.10 | 2021 | |
| Dexcom, INC. | $18.11 | 2022 | |
| Organon LLC | $15.45 | 2022 | |
| Amgen INC. | $15.10 | 2020 | |
| Amarin Pharma, INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.